BACKGROUND: We wanted to evaluate survival and functional morbidity following radiation treatment of brain tumors in children less than 4 years old. PROCEDURE: Outcome was evaluated for 222 children who were less than 4 years old when they were irradiated at University of Toronto Centres, 1958-1995. The status of the survivors with regard to focal neurological defects, vision, hearing, and education at last follow-up was recorded. In 23 adult survivors older than 21 years at last follow-up, information was obtained with regard to higher education, occupation, and living arrangements. RESULTS: The overall 10-year survival rate was 40%, not significantly different than the 45% for 776 4-16-year-olds with irradiated brain tumors treated at the same institutions. Forty-five percent of the survivors had no major focal neurological, visual, or hearing defects. There were no major differences in the frequencies of these criteria or of schooling between 0-2- and 2-4-year-olds. Among adult survivors, older than 21 at last follow-up, 26% successfully completed higher education, 31% were in full-time employment, and 37% had never been employed. For medulloblastoma, the 5-year survival rate was 61% for 30 children less than 3 years old and treated from 1975-1995. This compared favorably with recent reports of survival following primary chemotherapy with delayed or omitted radiation treatment. SUMMARY: Radiation treatment of a young child with a brain tumor was associated with cure in 1 of every 3 patients. Unfortunately, quality of life for many survivors was not good. Only one of every 3 adult survivors was able to have a normal life-style. This shortfall was the result of focal neurological defects which were present from the time of first treatment, and of the long-term effects of radiation treatment. CONCLUSIONS: The search for less toxic treatment remains appropriate, but is experimental and researchers must recognize that there may be a trade-off between morbidity and mortality.
BACKGROUND: We wanted to evaluate survival and functional morbidity following radiation treatment of brain tumors in children less than 4 years old. PROCEDURE: Outcome was evaluated for 222 children who were less than 4 years old when they were irradiated at University of Toronto Centres, 1958-1995. The status of the survivors with regard to focal neurological defects, vision, hearing, and education at last follow-up was recorded. In 23 adult survivors older than 21 years at last follow-up, information was obtained with regard to higher education, occupation, and living arrangements. RESULTS: The overall 10-year survival rate was 40%, not significantly different than the 45% for 776 4-16-year-olds with irradiated brain tumors treated at the same institutions. Forty-five percent of the survivors had no major focal neurological, visual, or hearing defects. There were no major differences in the frequencies of these criteria or of schooling between 0-2- and 2-4-year-olds. Among adult survivors, older than 21 at last follow-up, 26% successfully completed higher education, 31% were in full-time employment, and 37% had never been employed. For medulloblastoma, the 5-year survival rate was 61% for 30 children less than 3 years old and treated from 1975-1995. This compared favorably with recent reports of survival following primary chemotherapy with delayed or omitted radiation treatment. SUMMARY: Radiation treatment of a young child with a brain tumor was associated with cure in 1 of every 3 patients. Unfortunately, quality of life for many survivors was not good. Only one of every 3 adult survivors was able to have a normal life-style. This shortfall was the result of focal neurological defects which were present from the time of first treatment, and of the long-term effects of radiation treatment. CONCLUSIONS: The search for less toxic treatment remains appropriate, but is experimental and researchers must recognize that there may be a trade-off between morbidity and mortality.
Authors: Thora Gudrunardottir; Birgitta Lannering; Marc Remke; Michael D Taylor; Elizabeth M Wells; Robert F Keating; Roger J Packer Journal: Childs Nerv Syst Date: 2014-02-26 Impact factor: 1.475
Authors: Abdelkader E Ashour; Atallah F Ahmed; Ashok Kumar; Khairy M A Zoheir; Mourad A Aboul-Soud; Sheikh F Ahmad; Sabry M Attia; Adel R A Abd-Allah; Vino T Cheryan; Arun K Rishi Journal: Mol Cell Biochem Date: 2016-04-15 Impact factor: 3.396
Authors: Roberto Rivera-Luna; Aurora Medina-Sanson; Carlos Leal-Leal; Francisco Pantoja-Guillen; Marta Zapata-Tarrés; Rocio Cardenas-Cardos; Rafael Barrera-Gómez; Fernando Rueda-Franco Journal: Childs Nerv Syst Date: 2003-05-06 Impact factor: 1.475
Authors: Stefan Rutkowski; Nicolas Ulrich Gerber; Katja von Hoff; Astrid Gnekow; Udo Bode; Norbert Graf; Frank Berthold; Günter Henze; Johannes E A Wolff; Monika Warmuth-Metz; Niels Soerensen; Angela Emser; Holger Ottensmeier; Frank Deinlein; Paul-Gerhardt Schlegel; Rolf-Dieter Kortmann; Torsten Pietsch; Joachim Kuehl Journal: Neuro Oncol Date: 2008-09-25 Impact factor: 12.300
Authors: Antonio Pérez-Martínez; Victor Quintero; Marta González Vicent; Julián Sevilla; Miguel Angel Díaz; Luis Madero Journal: J Neurooncol Date: 2004 Mar-Apr Impact factor: 4.130
Authors: Tycho J Zuzak; Andrea Poretti; Barbara Drexel; Daniel Zehnder; Eugen Boltshauser; Michael A Grotzer Journal: Childs Nerv Syst Date: 2008-08-09 Impact factor: 1.475
Authors: Kavita K Mishra; Dev R Puri; Brian T Missett; Kathleen R Lamborn; Michael D Prados; Mitchel S Berger; Anuradha Banerjee; Nalin Gupta; William M Wara; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2006-02-22 Impact factor: 12.300